Fecal Occult Blood Test, Positive: What Study Next?

FDA approves updated indication for upadacitinib in ulcerative colitis and Crohn disease treatment, allowing use after one systemic therapy when TNF blockers are clinically inadvisable.

Recurrent C difficile requires pulse vancomycin therapy; fecal microbiota transplant shows promise.

FDA approves guselkumab as the first fully subcutaneous IL-23 inhibitor for ulcerative colitis, showing significant clinical benefits in trials.

The goals of therapy for patients with inflammatory bowel disorder include inducing and maintaining a steroid-free remission, preventing and treating the complications of the disease, minimizing treatment toxicity, achieving mucosal healing, and enhancing quality of life.

Using FMT over standard-of-care therapy may significantly reduce antibiotic use and well-known harms, including antibiotic resistance, study authors noted.

Your daily dose of the clinical news you may have missed.